Suggestions
Matthew Kerby
Head of Lead Discovery at X-37
Professional Background
Matthew Kerby is a seasoned professional in the pharmaceutical and biomedical industries, bringing a wealth of experience in sourcing, positioning, and developing a myriad of pharmaceutical products across diverse therapeutic areas. His extensive career has been marked by leadership roles in financing, partnering, and business development for several startups, showcasing his commitment to innovation and entrepreneurial spirit in the life sciences sector.
As the Head of Lead Discovery at X-37, Matthew has played a pivotal role in identifying and advancing new therapeutic candidates, leveraging his profound knowledge of applied and translational research to commercialize breakthrough technologies. His leadership has been instrumental in propelling startups like Corsair Pharma, Spitfire Pharma, and Menlo Therapeutics (formerly Tigercat Pharma) into the forefront of biopharmaceutical development.
Additionally, Matthew has contributed to the board representation for multiple organizations, demonstrating his capability and dedication to shaping the future of the industry through strategic guidance and oversight. His affiliation with Life Science Angels, particularly in their BIO Screening Committee, underscores his strong connections in the biotech investment community, further solidifying his influence in the field.
Education and Achievements
Matthew's educational background is distinguished, with an impressive array of degrees that equip him with a comprehensive understanding of both engineering principles and biomedical applications. He began his academic journey by earning a Bachelor of Science in Chemical Engineering from the University of California, Davis, where he built a solid foundation in the fundamental aspects of chemical processes.
He continued his studies with a Master of Science in Biomedical Engineering at California State University, Sacramento, which helped him transition into the biomedical field. His pursuit of knowledge didn't stop there; Matthew further advanced his academic achievements by obtaining a PhD in Biomedical Engineering from the prestigious Brown University, where he conducted pioneering research that added valuable insights into the commercialization of medical technologies.
Matthew also undertook postdoctoral studies in Bioengineering at Stanford University, where he further honed his skills in cutting-edge research. His extensive education is complemented by his status as a Professional Engineer (PE) licensed in California (#CH6165), showcasing his professional commitment to maintaining high standards in his engineering practice.
Achievements
Throughout his career, Matthew has a proven track record of successfully leading projects, establishing partnerships, and developing new technologies that contribute to the advancement of healthcare. His leadership in sourcing and developing pharmaceutical products has not only driven growth for emerging companies but also fostered innovation that benefits patients globally.
With a focus on applied and translational research, he has significantly impacted the way new therapeutics are commercialized, steering them from the lab into practical use in clinical settings. His unique blend of engineering expertise and biomedical knowledge has allowed him to address complex challenges in product development and bring novel solutions to market.
Moreover, Matthew's involvement with various organizations and committees exhibits his passion for fostering innovation in the life sciences arena. As a member of the BIO Screening Committee at Life Science Angels, he has the opportunity to evaluate and guide new biotech ventures, playing a crucial role in determining the future landscape of pharmaceuticals and therapeutics. His board representation speaks to his reputation as a trusted advisor and leader committed to advancing the mission of the organizations he serves.
In summary, Matthew Kerby exemplifies the ideal blend of technical expertise, research acumen, and entrepreneurial spirit that drives progress in the pharmaceutical and biomedical sectors. His extensive experience in various therapeutic areas and leadership roles has positioned him as a notable figure in the industry, with a bright future ahead as he continues to innovate and inspire others in the field.
